Touyun Biotech Group Limited has provided a quarterly update on its ongoing efforts to resolve the audit qualification raised in its 2024 Annual Report. The company has taken active initiatives aimed at enhancing the speed of product distribution and expanding customer reach. Specifically, Touyun Biotech Group has been in ongoing discussions with leading supermarket chains and groups, expressing mutual interest in establishing formal agreements for product distribution and sales. Additionally, the Group is collaborating with trending Key Opinion Leaders (KOLs) to promote its products and boost sales through livestream commerce channels. The Board emphasized its commitment to proactively implementing relevant measures to address the uncertainties related to going concern, which are associated with the disclaimer of opinion by the auditors. Shareholders and potential investors are advised to exercise caution when dealing in the company's securities, and the Board will continue to make further announcements as necessary. The statement was issued under the authority of the Board, chaired by Mr. Wang Liang, on 30 September 2025.